Drug Discovery World
MAY 21, 2024
Modern experimental procedures, such as immunisation, B-cell screening, and synthetic library generation, have been pivotal in developing approximately 80 FDA-approved antibody therapeutics. These targets, along with many others, are universally deemed as ‘difficult-to-drug’ targets.
XTalks
AUGUST 3, 2022
In this episode, Ayesha discussed the FDA approval of Azurity Pharmaceutical’s Zonisade (zonisamide oral suspension) as an adjunct therapy for the treatment of seizures in adults and pediatric patients 16 years of age and older with epilepsy. The drug is the first FDA approved oral suspension form of zonisamide.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
NOVEMBER 29, 2023
Researchers have created a mathematical model that can accurately depict Alzheimer’s disease progression in individual patients, paving the way for personalised treatment and faster development of therapies. The post Mathematical model can speed up Alzheimer’s drug development appeared first on Drug Discovery World (DDW).
Drug Discovery World
MAY 3, 2023
Patients with diabetes mellitus have an increased risk of cardiovascular events and endothelial dysfunction is an important factor for this development” said Jan Nilsson, Professor in Experimental Cardiology, Lund University, and principal investigator in the trial.
Advarra
AUGUST 16, 2022
Orphan drugs have historically faced a number of barriers, such as limited research and development (R&D) investment due to an expected lack of profitability as well as challenges in clinical trial design and recruitment. Before 1983, only 38 orphan drugs had received U.S. Food and Drug Administration (FDA) approval.
Delveinsight
AUGUST 12, 2021
Through its development and use of different algorithms, Zebra Medical has been able to recognize visual symptoms for diseases such as breast cancer , osteoporosis , and fatty liver , as well as conditions such as aneurysms and brain bleeds. The original agreement had Finch responsible for early-stage development through phase 2 studies.
Drug Discovery World
MARCH 7, 2023
Powers taught for more than six years at the National Institutes of Health, on medical product development and commercialisation, and at Georgetown Law School as an adjunct professor. She founded Neuroute in 2019, with the aim of empowering patients from diverse backgrounds to participate in drug trials.
Expert insights. Personalized for you.
59 
Let's personalize your content